ArticleFrontiers in pharmacology2017

Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule.

Antonello Di Paolo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.